CEP-1347 (Cephalon).
Mucke
Hermann A M
HA
HM Pharma Consultancy, Enenkelstrasse 28/32, A-1160 Vienna, Austria. h.mucke@hmpharmacon.com
D000818:Animals; D002227:Carbazoles / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D000075202:Contraindications; D006801:Humans; D007211:Indoles / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D018696:Neuroprotective Agents / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D013329:Structure-Activity Relationship
D002227:Carbazoles; D007211:Indoles; D018696:Neuroprotective Agents; C106592:3,9-bis((ethylthio)methyl)-K-252a